Table 3.
Number of patients who experienced secondary outcomes
| Outcome | Eplerenone (n=77) | Placebo (n=77) | Relative Risk (95% CI) |
|---|---|---|---|
| Hyperkalemia | |||
| Defined as >6 mEq/L | 19 (24.7) | 14 (18.2) | 1.4 (0.7 to 2.5) |
| Defined as >6.5 mEq/L | 9 (11.7) | 2 (2.6) | 4.5 (1.0 to 20.2) |
| Defined as >7 mEq/L | 4 (5.2) | 0 (0) | NA |
| Significant hypotension | 16 (20.8) | 14 (18.2) | 1.1 (0.6 to 2.2) |
| Deaths | – | – | – |
| Vascular | 1 (1.3) | 2 (2.6) | 0.5 (0.0 to 5.4) |
| Any cause | 1 (1.3) | 2 (2.6) | 0.5 (0.0 to 5.4) |
| Nonfatal vascular event | 3 (3.9) | 4 (5.2) | 0.8 (0.2 to 3.2) |
| Fatal or nonfatal vascular event | 4 (5.2) | 6 (7.8) | 0.7 (0.2 to 2.3) |
All analyses use the intention-to-treat population. 95% CI, 95% confidence interval; NA, not applicable.